M. Progressive, M. Relapsing-remitting, and . Patients, Note that the Relapsing-remitting group comprises the clinical groups: RR-MS Remission, RR-MS Active, RESPONDERS, NON RESPONDERS and RELAPSES. The Progressive group comprises Secondary (SP-MS) and Primary-progressive patients

J. Tzartos, M. Friese, M. Craner, J. Palace, J. Newcombe et al., Interleukin-17 Production in Central Nervous System-Infiltrating T Cells and Glial Cells Is Associated with Active Disease in Multiple Sclerosis, The American Journal of Pathology, vol.172, issue.1, pp.146-55, 2007.
DOI : 10.2353/ajpath.2008.070690

C. Malmestrom, B. Andersson, S. Haghighi, and J. Lycke, IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: Implications for their possible immunopathogenic roles, Journal of Neuroimmunology, vol.175, issue.1-2, pp.176-82, 2006.
DOI : 10.1016/j.jneuroim.2006.03.004

P. Rieckmann, M. Albrecht, B. Kitze, T. Weber, H. Tumani et al., Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis, Neurology, vol.44, issue.8, pp.1523-1529, 1994.
DOI : 10.1212/WNL.44.8.1523

S. Spuler, T. Yousry, A. Scheller, R. Voltz, E. Holler et al., Multiple sclerosis: prospective analysis of TNF-alpha and 55 kDa TNF receptor in CSF and serum in correlation with clinical and MRI activity, Journal of neuroimmunology, vol.66, issue.12, pp.57-64, 1996.

K. Fassbender, A. Ragoschke, S. Rossol, A. Schwartz, O. Mielke et al., Increased release of interleukin-12p40 in MS: Association with intracerebral inflammation, Neurology, vol.51, issue.3, pp.753-761, 1998.
DOI : 10.1212/WNL.51.3.753

A. Van-boxel-dezaire, M. Smits, S. Van-trigt-hoff, J. Killestein, J. Van-houwelingen et al., Cytokine and IL-12 receptor mRNA discriminate between different clinical subtypes in multiple sclerosis, Journal of Neuroimmunology, vol.120, issue.1-2, pp.152-60, 2001.
DOI : 10.1016/S0165-5728(01)00398-8

H. Bartosik-psujek and Z. Stelmasiak, Correlations between IL-4, IL-12 levels and CCL2, CCL5 levels in serum and cerebrospinal fluid of multiple sclerosis patients, Journal of Neural Transmission, vol.112, issue.6, pp.797-803, 2005.
DOI : 10.1007/s00702-004-0225-9

C. Polman, S. Reingold, B. Banwell, M. Clanet, J. Cohen et al., Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria, Annals of Neurology, vol.64, issue.suppl 2, pp.292-302, 2011.
DOI : 10.1002/ana.22366

J. Kurtzke, Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS), Neurology, vol.33, issue.11, pp.1444-52, 1983.
DOI : 10.1212/WNL.33.11.1444

E. Ubogu, M. Cossoy, and R. Ransohoff, The expression and function of chemokines involved in CNS inflammation Trends in pharmacological sciences, Epub, vol.27, issue.1, pp.48-55, 2005.

A. Szczucinski and J. Losy, Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies, Acta Neurologica Scandinavica, vol.57, issue.3, pp.137-183, 2007.
DOI : 10.1002/eji.200535195

R. Ransohoff, The Chemokine System in Neuroinflammation: An Update, The Journal of Infectious Diseases, vol.186, issue.s2, pp.152-158, 2002.
DOI : 10.1086/344266

K. Hulkower, C. Brosnan, D. Aquino, W. Cammer, S. Kulshrestha et al., Expression of CSF- 1, c-fms, and MCP-1 in the central nervous system of rats with experimental allergic encephalomyelitis

R. Godiska, D. Chantry, G. Dietsch, and P. Gray, Chemokine expression in murine experimental allergic encephalomyelitis, Journal of Neuroimmunology, vol.58, issue.2, pp.167-76, 1995.
DOI : 10.1016/0165-5728(95)00008-P

T. Owens and S. Sriram, The immunology of multiple sclerosis and its animal model, experimental allergic encephalomyelitis, Neurologic clinics. Epub, vol.13, issue.1, pp.51-73, 1995.

E. Bettelli and L. Nicholson, The Role of Cytokines in Experimental Autoimmune Encephalomyelitis, Archivum immunologiae et therapiae experimentalis. Epub, vol.48, issue.5, pp.389-98, 2000.
DOI : 10.1007/978-94-010-0981-2_9

A. Rajan, V. Asensio, I. Campbell, and C. Brosnan, Experimental Autoimmune Encephalomyelitis on the SJL Mouse: Effect of ???? T Cell Depletion on Chemokine and Chemokine Receptor Expression in the Central Nervous System, The Journal of Immunology, vol.164, issue.4, pp.2120-3005, 2000.
DOI : 10.4049/jimmunol.164.4.2120

C. Gerard and B. Rollins, Chemokines and disease, Nature Immunology, vol.2, issue.2, pp.108-123, 2001.
DOI : 10.1038/84209

N. Godessart and S. Kunkel, Chemokines in autoimmune disease Current opinion in immunology, Epub, vol.131026, issue.601, pp.670-675, 2001.

S. Ibrahim, E. Mix, T. Bottcher, D. Koczan, R. Gold et al., Gene expression profiling of the nervous system in murine experimental autoimmune encephalomyelitis, Brain, vol.124, issue.10, pp.1927-1965, 2001.
DOI : 10.1093/brain/124.10.1927

R. Carmody, B. Hilliard, K. Maguschak, L. Chodosh, and Y. Chen, Genomic scale profiling of autoimmune inflammation in the central nervous system: the nervous response to inflammation, Journal of Neuroimmunology, vol.133, issue.1-2, pp.95-107, 2002.
DOI : 10.1016/S0165-5728(02)00366-1

C. Lock, G. Hermans, R. Pedotti, A. Brendolan, E. Schadt et al., Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis, Nature Medicine, vol.158, issue.5, pp.500-508, 2002.
DOI : 10.1038/ng0896-464

A. Glabinski, B. Bielecki, and R. Ransohoff, Chemokine Upregulation Follows Cytokine Expression in Chronic Relapsing Experimental Autoimmune Encephalomyelitis, Scandinavian Journal of Immunology, vol.183, issue.1, pp.81-89, 2003.
DOI : 10.1046/j.1365-3083.2003.01285.x

J. Skuljec, H. Sun, R. Pul, K. Benardais, D. Ragancokova et al., CCL5 induces a pro-inflammatory profile in microglia in vitro, Cellular Immunology, vol.270, issue.2, pp.164-71, 2011.
DOI : 10.1016/j.cellimm.2011.05.001

M. Bugeja, D. Booth, B. Bennetts, R. Heard, J. Rubio et al., An investigation of polymorphisms in the 17q11.2-12 CC chemokine gene cluster for association with multiple sclerosis in Australians, BMC Medical Genetics, vol.72, issue.4, pp.64-1550395, 2006.
DOI : 10.1172/JCI117788

J. Ockinger, P. Stridh, A. Beyeen, F. Lundmark, M. Seddighzadeh et al., Genetic variants of CC chemokine genes in experimental autoimmune encephalomyelitis, multiple sclerosis and rheumatoid arthritis, Genes and Immunity, vol.179, issue.2, pp.142-54, 2009.
DOI : 10.1016/j.jneuroim.2009.01.014

I. Banisor, T. Leist, and B. Kalman, Involvement of beta-chemokines in the development of inflammatory demyelination, Journal of neuroinflammation. Epub, vol.2, issue.17, p.554759, 1742.

M. Adzemovic, J. Ockinger, M. Zeitelhofer, S. Hochmeister, A. Beyeen et al., Expression of Ccl11 Associates with Immune Response Modulation and Protection against Neuroinflammation in Rats, PLoS ONE, vol.166, issue.7, pp.39794-3397980, 2012.
DOI : 10.1371/journal.pone.0039794.s008

W. Jung, E. Castren, M. Odenthal, V. Woude, G. Ishii et al., Expression and functional interaction of hepatocyte growth factor- scatter factor and its receptor c-met in mammalian brain, The Journal of Cell Biology, vol.126, issue.2, pp.485-94, 1994.
DOI : 10.1083/jcb.126.2.485

P. Lalive, R. Paglinawan, G. Biollaz, E. Kappos, D. Leone et al., TGF-?-treated microglia induce oligodendrocyte precursor cell chemotaxis through the HGF-c-Met pathway, European Journal of Immunology, vol.120, issue.3, pp.727-764, 2005.
DOI : 10.1002/eji.200425430

Y. Zhang, J. Denham, and R. Thies, Oligodendrocyte progenitor cells derived from human embryonic stem cells express neurotrophic factors Stem cells and development, Epub, vol.15, issue.6, pp.943-52, 2006.

S. Jeong, M. Kwon, H. Lee, E. Joe, J. Lee et al., Hepatocyte growth factor reduces astrocytic scar formation and promotes axonal growth beyond glial scars after spinal cord injury, Experimental Neurology, vol.233, issue.1, pp.312-334, 2011.
DOI : 10.1016/j.expneurol.2011.10.021

M. Park, M. Dean, C. Cooper, M. Schmidt, O. Brien et al., Mechanism of met oncogene activation, Cell, vol.45, issue.6, pp.895-904, 1986.
DOI : 10.1016/0092-8674(86)90564-7

D. Bottaro, J. Rubin, D. Faletto, A. Chan, T. Kmiecik et al., Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product, Science, vol.251, issue.4995, pp.802-806, 1991.
DOI : 10.1126/science.1846706

S. Honda, M. Kagoshima, A. Wanaka, M. Tohyama, K. Matsumoto et al., Localization and functional coupling of HGF and c-Met/HGF receptor in rat brain: implication as neurotrophic factor, Molecular Brain Research, vol.32, issue.2, pp.197-210, 1995.
DOI : 10.1016/0169-328X(95)00075-4

C. Achim, S. Katyal, C. Wiley, M. Shiratori, G. Wang et al., Expression of HGF and cMet in the developing and adult brain, Developmental Brain Research, vol.102, issue.2, pp.299-303, 1997.
DOI : 10.1016/S0165-3806(97)00108-9

R. Van-der-voort, T. Taher, R. Keehnen, L. Smit, M. Groenink et al., Paracrine regulation of germinal center B cell adhesion through the c-met-hepatocyte growth factor/scatter factor pathway, The Journal of experimental medicine. PMID, vol.18516, issue.12, pp.2121-2152, 1997.

D. Adams, L. Harvath, D. Bottaro, R. Interrante, G. Catalano et al., Hepatocyte growth factor and macrophage inflammatory protein 1 beta: structurally distinct cytokines that induce rapid cytoskeletal changes and subset-preferential migration in T cells., Proceedings of the National Academy of Sciences, vol.91, issue.15, pp.7144-7152, 1994.
DOI : 10.1073/pnas.91.15.7144

S. Kurz, S. Diebold, T. Hieronymus, T. Gust, P. Bartunek et al., The impact of c-met/scatter factor receptor on dendritic cell migration, 7<1832::AID-IMMU1832>3.0.CO;2-2 PMID, pp.1832-1840, 2002.
DOI : 10.1002/1521-4141(200207)32:7<1832::AID-IMMU1832>3.0.CO;2-2

J. Baek, C. Birchmeier, M. Zenke, and T. Hieronymus, The HGF Receptor/Met Tyrosine Kinase Is a Key Regulator of Dendritic Cell Migration in Skin Immunity, The Journal of Immunology, vol.189, issue.4, pp.1699-707, 2012.
DOI : 10.4049/jimmunol.1200729

Y. Tsuboi, K. Kakimoto, H. Akatsu, Y. Daikuhara, and T. Yamada, Hepatocyte growth factor in cerebrospinal fluid in neurologic disease, Acta Neurologica Scandinavica, vol.251, issue.2, pp.99-103, 2002.
DOI : 10.1016/S0006-8993(97)00958-X

M. Kern, S. Bamborschke, M. Nekic, D. Schubert, C. Rydin et al., CONCENTRATIONS OF HEPATOCYTE GROWTH FACTOR IN CEREBROSPINAL FLUID UNDER NORMAL AND DIFFERENT PATHOLOGICAL CONDITIONS, Cytokine, vol.14, issue.3, pp.170-176, 2001.
DOI : 10.1006/cyto.2001.0875

A. Muller, E. Jun, H. Conlon, and S. Sadiq, Cerebrospinal hepatocyte growth factor levels correlate negatively with disease activity in multiple sclerosis, Journal of Neuroimmunology, vol.251, issue.1-2, pp.80-86, 2012.
DOI : 10.1016/j.jneuroim.2012.06.008

A. Compston, J. Zajicek, J. Sussman, A. Webb, G. Hall et al., Review: Glial lineages and myelination in the central nervous system, Journal of Anatomy, vol.190, issue.2, pp.161-200, 1997.
DOI : 10.1046/j.1469-7580.1997.19020161.x

O. Gonzalez-perez, R. Romero-rodriguez, M. Soriano-navarro, J. Garcia-verdugo, and A. Alvarez-buylla, Epidermal Growth Factor Induces the Progeny of Subventricular Zone Type B Cells to Migrate and Differentiate into Oligodendrocytes, Stem Cells, vol.9, issue.8, pp.2032-2075, 2009.
DOI : 10.1002/stem.119

D. Del-barco, E. Montero, R. Coro-antich, E. Brown, J. Suarez-alba et al., Coadministration of epidermal growth factor and growth hormone releasing peptide-6 improves clinical recovery in experimental autoimmune encephalitis. Restorative neurology and neuroscience, Epub, vol.29, issue.4, pp.243-52, 2011.

G. Scalabrino, D. Galimberti, E. Mutti, D. Scalabrini, D. Veber et al., Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis, Brain Research, vol.1333, pp.64-71, 2010.
DOI : 10.1016/j.brainres.2010.03.073

D. Clemente, M. Ortega, F. Arenzana, and F. De-castro, FGF-2 and Anosmin-1 Are Selectively Expressed in Different Types of Multiple Sclerosis Lesions, Journal of Neuroscience, vol.31, issue.42, pp.14899-909, 2011.
DOI : 10.1523/JNEUROSCI.1158-11.2011

A. Butt and J. Dinsdale, Fibroblast growth factor 2 induces loss of adult oligodendrocytes and myelin in vivo, Experimental Neurology, vol.192, issue.1, pp.125-158, 2005.
DOI : 10.1016/j.expneurol.2004.11.007

D. Goddard, M. Berry, S. Kirvell, and A. Butt, Fibroblast Growth Factor-2 Inhibits Myelin Production by Oligodendrocytes in Vivo, Molecular and Cellular Neuroscience, vol.18, issue.5, pp.557-69, 2001.
DOI : 10.1006/mcne.2001.1025

L. Magy, C. Mertens, V. Avellana-adalid, M. Keita, F. Lachapelle et al., Inducible expression of FGF2 by a rat oligodendrocyte precursor cell line promotes CNS myelination in vitro, Experimental Neurology, vol.184, issue.2
DOI : 10.1016/j.expneurol.2003.08.019

A. Rottlaender, H. Villwock, K. Addicks, and S. Kuerten, Neuroprotective role of fibroblast growth factor-2 in experimental autoimmune encephalomyelitis, Immunology, vol.275, issue.3, pp.370-378, 2011.
DOI : 10.1111/j.1365-2567.2011.03450.x

P. Sarchielli, D. Filippo, M. Ercolani, M. Chiasserini, D. Mattioni et al., Fibroblast growth factor-2 levels are elevated in the cerebrospinal fluid of multiple sclerosis patients, Neuroscience Letters, vol.435, issue.3, pp.223-231, 2008.
DOI : 10.1016/j.neulet.2008.02.040

N. Ferrara and K. Alitalo, Clinical applications of angiogenic growth factors and their inhibitors, Nature Medicine, vol.5, issue.12, pp.1359-64, 1999.
DOI : 10.1038/70928

P. Carmeliet, Mechanisms of angiogenesis and arteriogenesis, Nature Medicine, vol.6, issue.4, pp.389-95, 2000.
DOI : 10.1038/74651

G. Yancopoulos, S. Davis, N. Gale, J. Rudge, S. Wiegand et al., Vascular-specific growth factors and blood vessel formation, Nature, vol.407, issue.6801, pp.242-250, 2000.
DOI : 10.1038/35025215

C. Cursiefen, L. Chen, L. Borges, D. Jackson, J. Cao et al., VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment, Journal of Clinical Investigation, vol.113, issue.7, pp.1040-50, 2004.
DOI : 10.1172/JCI20465

S. Croll, R. Ransohoff, N. Cai, Q. Zhang, F. Martin et al., VEGF-mediated inflammation precedes angiogenesis in adult brain, Experimental Neurology, vol.187, issue.2, pp.388-402, 2004.
DOI : 10.1016/j.expneurol.2004.02.010

C. Ruiz-de-almodovar, D. Lambrechts, M. Mazzone, and P. Carmeliet, Role and Therapeutic Potential of VEGF in the Nervous System, Physiological Reviews, vol.89, issue.2, pp.607-48607, 2008.
DOI : 10.1152/physrev.00031.2008

J. Hiehle, . Jr, R. Lenkinski, R. Grossman, V. Dousset et al., Correlation of spectroscopy and magnetization transfer imaging in the evaluation of demyelinating lesions and normal appearing white matter in multiple sclerosis, Magnetic Resonance in Medicine, vol.17, issue.3, pp.285-93, 1994.
DOI : 10.1002/mrm.1910320303

J. Su, M. Osoegawa, T. Matsuoka, M. Minohara, M. Tanaka et al., Upregulation of vascular growth factors in multiple sclerosis: Correlation with MRI findings, S0022-510X(05)00417-X, pp.21-30, 2005.
DOI : 10.1016/j.jns.2005.11.006

U. Graumann, R. Reynolds, A. Steck, and N. Schaeren-wiemers, Molecular Changes in Normal Appearing White Matter in Multiple Sclerosis are Characteristic of Neuroprotective Mechanisms Against Hypoxic Insult, Brain Pathology, vol.73, issue.4, pp.554-7306, 2003.
DOI : 10.1111/j.1750-3639.2003.tb00485.x

M. Proescholdt, S. Jacobson, N. Tresser, E. Oldfield, and M. Merrill, Vascular Endothelial Growth Factor Is Expressed in Multiple Sclerosis Plaques and Can Induce Inflammatory Lesions in Experimental Allergic Encephalomyelitis Rats, Journal of Neuropathology & Experimental Neurology, vol.61, issue.10, pp.61914-61939, 2002.
DOI : 10.1093/jnen/61.10.914

E. Iacobaeus, P. Amoudruz, M. Strom, M. Khademi, L. Brundin et al., The Expression of VEGF-A Is Down Regulated in Peripheral Blood Mononuclear Cells of Patients with Secondary Progressive Multiple Sclerosis, PLoS ONE, vol.34, issue.5, p.19138, 2011.
DOI : 10.1371/journal.pone.0019138.s004

E. Scarpini, D. Galimberti, P. Baron, R. Clerici, M. Ronzoni et al., IP-10 and MCP-1 levels in CSF and serum from multiple sclerosis patients with different clinical subtypes of the disease, Journal of the Neurological Sciences, vol.195, issue.1, pp.41-47, 2002.
DOI : 10.1016/S0022-510X(01)00680-3

T. Sorensen, F. Sellebjerg, C. Jensen, R. Strieter, and R. Ransohoff, Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis, European Journal of Neurology, vol.103, issue.6, pp.665-72, 2001.
DOI : 10.1016/S1074-7613(00)80165-X

E. Sindern, Y. Niederkinkhaus, M. Henschel, L. Ossege, T. Patzold et al., Differential release of beta-chemokines in serum and CSF of patients with relapsing-remitting multiple sclerosis, Acta Neurologica Scandinavica, vol.154, issue.2, pp.88-91, 2001.
DOI : 10.1016/S0165-5728(97)00040-4

K. Narikawa, T. Misu, K. Fujihara, I. Nakashima, S. Sato et al., CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis, Journal of Neuroimmunology, vol.149, issue.1-2, pp.182-188, 2004.
DOI : 10.1016/j.jneuroim.2003.12.010

H. Amano, K. Morimoto, M. Senba, H. Wang, Y. Ishida et al., Essential Contribution of Monocyte Chemoattractant Protein-1/C-C Chemokine Ligand-2 to Resolution and Repair Processes in Acute Bacterial Pneumonia, The Journal of Immunology, vol.172, issue.1, pp.398-409, 2003.
DOI : 10.4049/jimmunol.172.1.398

T. Sorensen, T. M. Jensen, J. Pierce, V. Lucchinetti, C. Folcik et al., Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients, Journal of Clinical Investigation, vol.103, issue.6, pp.807-822, 1999.
DOI : 10.1172/JCI5150

J. Simpson, J. Newcombe, M. Cuzner, and M. Woodroofe, Expression of monocyte chemoattractant pro- tein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions, Journal of neuroimmunology, vol.8417, issue.206, pp.238-287, 1998.

H. Bartosik-psujek and Z. Stelmasiak, The levels of chemokines CXCL8, CCL2 and CCL5 in multiple sclerosis patients are linked to the activity of the disease, European Journal of Neurology, vol.103, issue.1, pp.49-54, 2004.
DOI : 10.1016/S1074-7613(00)80165-X

T. Misu, H. Onodera, K. Fujihara, K. Matsushima, Y. O. Okita et al., Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: imbalance of Th1/Th2-associated chemokine signaling, Journal of Neuroimmunology, vol.114, issue.1-2, pp.207-219, 2001.
DOI : 10.1016/S0165-5728(00)00456-2

H. Bartosik-psujek and Z. Stelmasiak, Steroid Therapy Altered Serum Levels of CCL2 and CCL5 Chemokines in Multiple Sclerosis Patients during Relapse, European Neurology, vol.52, issue.4, pp.237-278, 2004.
DOI : 10.1159/000082164

K. Balashov, J. Rottman, H. Weiner, and W. Hancock, CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1?? and IP-10 are expressed in demyelinating brain lesions, Proceedings of the National Academy of Sciences, vol.96, issue.12, pp.6873-6881, 1999.
DOI : 10.1073/pnas.96.12.6873

Y. Zang, A. Samanta, J. Halder, J. Hong, M. Tejada-simon et al., Aberrant T cell migration toward RANTES and MIP-1 alpha in patients with multiple sclerosis. Overexpression of chemokine receptor CCR5, Brain: a journal of neurology, vol.12326, issue.08, pp.1874-82, 2000.

E. Comini-frota, A. Teixeira, J. Angelo, M. Andrade, D. Brum et al., Evaluation of Serum Levels of Chemokines during Interferon-?? Treatment in Multiple Sclerosis Patients, CNS Drugs, vol.104, issue.2, pp.971-81, 2011.
DOI : 10.2165/11595060-000000000-00000

S. Cepok, H. Schreiber, S. Hoffmann, D. Zhou, O. Neuhaus et al., Enhancement of Chemokine Expression by Interferon Beta Therapy in Patients With Multiple Sclerosis, Archives of Neurology, vol.66, issue.10, pp.1216-1239, 2009.
DOI : 10.1001/archneurol.2009.138

F. Sellebjerg, M. Krakauer, D. Hesse, L. Ryder, I. Alsing et al., response to interferon-?? treatment in multiple sclerosis using DNA-array evaluation, European Journal of Neurology, vol.70, issue.12, pp.1291-1299, 2009.
DOI : 10.1111/j.1468-1331.2009.02716.x

C. Iarlori, M. Reale, D. Luca, G. , D. Iorio et al., Interferon ??-1b modulates MCP-1 expression and production in relapsing???remitting multiple sclerosis, Journal of Neuroimmunology, vol.123, issue.1-2, pp.170-179, 2002.
DOI : 10.1016/S0165-5728(01)00487-8

A. Noronha, A. Toscas, and M. Jensen, Interferon ?? decreases T cell activation and interferon ?? production in multiple sclerosis, Journal of Neuroimmunology, vol.46, issue.1-2, pp.145-53, 1993.
DOI : 10.1016/0165-5728(93)90244-S

K. Balashov, D. Smith, S. Khoury, D. Hafler, and H. Weiner, Increased interleukin 12 production in progressive multiple sclerosis: Induction by activated CD4+ T cells via CD40 ligand, Proceedings of the National Academy of Sciences, vol.94, issue.2, pp.599-603, 1997.
DOI : 10.1073/pnas.94.2.599

M. Baggiolini, Chemokines and leukocyte traffic, Nature, vol.392, issue.6676, pp.565-573, 1998.
DOI : 10.1038/33340